Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
These insights may help contextualize individual GLP-1 pathway biology and support a more informed conversation with your provider about medication selection and expected outcomes
it is prepared by a 503A pharmacy for an individual patient's prescription under that regulatory pathway
FuturHealth Among the First to Offer Eli Lilly's Oral GLP-1, Orforglipron, Expanding Access to Next-Generation, Non-Injectable Treatment FuturHealth Among the First to Offer Eli Lilly's Oral GLP-1, Orforglipron, Expanding Access to Next-Generation, Non-Injectable Treatment PR Newswire SAN DIEGO, April 28, 2026 The once-daily pill is now available through FuturHealth with home delivery SAN DIEGO, April 28, 2026 /PRNewswire/ -- FuturHealth, a clinically-guided health platform designed to support long-term health beyond weight loss, today announced that it is expanding its suite of care options to include orforglipron, Eli Lilly's oral GLP-1 receptor agonist under brand name Foundayo1, as part of a growing shift toward more accessible, non-injectable treatment options
Even if you use TomorrowsRx, your primary care provider should be aware of any prescription medications you're taking, including weight loss medications, so they can coordinate your overall care effectively
